In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.
A study of Chinese adults has found a protective benefit with daily green tea consumption against incident type 2 diabetes (T2D), as well as all-cause mortality in patients with T2D. However, the associations for other types of tea are unclear.
In type 2 diabetes (T2D) patients initiating second-line therapy, a delay in glucose-lowering treatment intensification appears to reduce the likelihood of reaching recommended treatment goals, a study has found.
Ertugliflozin significantly improves glycaemic outcomes in patients with type 2 diabetes (T2D) who have stage 3 chronic kidney disease (CKD), according to a subgroup analysis of the VERTIS CV* trial presented at ADA 2021.